Masimo (NASDAQ:MASI) Price Target Raised to $210.00 at Piper Sandler

Masimo (NASDAQ:MASI) had its target price upped by Piper Sandler from $180.00 to $210.00 in a report issued on Wednesday,Benzinga reports. Piper Sandler currently has an overweight rating on the medical equipment provider’s stock.

Several other research analysts also recently commented on the company. Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective for the company in a research note on Wednesday, November 6th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Wells Fargo & Company boosted their price target on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, BTIG Research boosted their target price on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Masimo currently has a consensus rating of “Moderate Buy” and an average target price of $175.67.

Masimo Stock Down 0.3 %

Shares of NASDAQ MASI opened at $169.52 on Wednesday. The firm has a market cap of $9.08 billion, a price-to-earnings ratio of 116.91 and a beta of 1.01. The company’s 50-day simple moving average is $160.45 and its 200-day simple moving average is $134.73. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo has a 52-week low of $101.61 and a 52-week high of $180.97.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same period in the previous year, the firm posted $0.63 EPS. Masimo’s revenue was up 5.4% compared to the same quarter last year. Equities analysts predict that Masimo will post 4.03 EPS for the current fiscal year.

Institutional Trading of Masimo

Several hedge funds have recently made changes to their positions in MASI. NBC Securities Inc. lifted its holdings in Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 73 shares during the last quarter. MML Investors Services LLC lifted its stake in shares of Masimo by 4.9% in the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 96 shares during the last quarter. Fifth Third Bancorp grew its holdings in shares of Masimo by 16.4% during the 2nd quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock worth $88,000 after purchasing an additional 98 shares during the period. Oak Thistle LLC increased its position in shares of Masimo by 5.2% during the 2nd quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock worth $262,000 after purchasing an additional 103 shares during the last quarter. Finally, HHM Wealth Advisors LLC raised its holdings in Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after buying an additional 125 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.